Has Glenda Kaminski received payments from drug or device companies?

Yes. Drug and device makers reported $4,925 in general payments to Glenda Kaminski across 64 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Glenda Kaminski did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Glenda Kaminski come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Glenda Kaminski

Oncology · Lakeland, FLNPI 1073072203

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.2% of the total across 64 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AstraZeneca at 33.5% of the total.

$4,925in general payments, 2019–2025

Across 64 payments — averaging $76.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$2K
E.r. Squibb & Sons, L.L.C.$775
AbbVie$254
Astellas Pharma US Inc$223
Jazz Pharmaceuticals Inc.$216
Daiichi Sankyo Inc.$158
plus $2K from 21 others

What the payments were for

Food & beverage$4,74096%
Education$1854%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	18	$1,651
E.r. Squibb & Sons, L.L.C.	8	$775
AbbVie	3	$254
Astellas Pharma US Inc	4	$223
Jazz Pharmaceuticals Inc.	2	$216
Daiichi Sankyo Inc.	2	$158
BD	2	$154
Stemline Therapeutics Inc.	2	$135
Taiho Oncology, Inc.	2	$126
Sobi, Inc	1	$125
Pfizer	1	$120
Stryker	1	$117
Bayer	1	$104
Rigel Pharmaceuticals, Inc.	1	$94
Caris MPI, Inc.	2	$84
Novocure Inc.	1	$78
Takeda Pharmaceuticals U.S.A., Inc.	1	$78
Puma Biotechnology, Inc.	1	$76
Inari Medical, Inc.	1	$64
Sanofi	1	$59
Novartis	2	$52
Medline Industries LP	2	$43
Gilead	1	$42
Pharmacosmos Therapeutics Inc.	1	$41
Incyte Corporation	1	$19
Johnson & Johnson	1	$18
Springworks Therapeutics, Inc.	1	$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,925 in reported general payments places this provider in the 60th percentile of 24 oncology providers in Florida.

See all oncology providers in Florida →

Other oncology in Lakeland

Sara BeelerTampa$337K
Michelle RampersadSebring$34K
Janell VerkadenOrmond Beach$19K
Kimberly TopeTampa$16K
Aaron DohenySt Petersburg$14K
Naima Vera-SommersTampa$11K
Amber AlbaughLecanto$9K
Natalie GessnerClearwater$8K
Melissa BlandfordHudson$6K
Lee PavelBonita Springs$5K

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →